Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension

Mark E. Orcholski, Artyom Khurshudyan, Elya A. Shamskhou, Ke Yuan, Ian Y. Chen, Sean D. Kodani, Christophe Morisseau, Bruce D. Hammock, Ellen M. Hong, Ludmila Alexandrova, Tero Pekka Alastalo, Gerald Berry, Roham T. Zamanian, Vinicio A. De Jesus Perez

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Pulmonary arterial hypertension is a complication of methamphetamine use (METH-PAH), but the pathogenic mechanisms are unknown. Given that cytochrome P450 2D6 (CYP2D6) and carboxylesterase 1 (CES1) are involved in metabolism of METH and other amphetamine-like compounds, we postulated that loss of function variants could contribute to METH-PAH. Although no difference in CYP2D6 expression was seen by lung immunofluorescence, CES1 expression was significantly reduced in endothelium of METH-PAH microvessels. Mass spectrometry analysis showed that healthy pulmonary microvascular endothelial cells (PMVECs) have the capacity to both internalize and metabolize METH. Furthermore, whole exome sequencing data from 18 METH-PAH patients revealed that 94.4% of METH-PAH patients were heterozygous carriers of a single nucleotide variant (SNV; rs115629050) predicted to reduce CES1 activity. PMVECs transfected with this CES1 variant demonstrated significantly higher rates of METH-induced apoptosis. METH exposure results in increased formation of reactive oxygen species (ROS) and a compensatory autophagy response. Compared with healthy cells, CES1-deficient PMVECs lack a robust autophagy response despite higher ROS, which correlates with increased apoptosis. We propose that reduced CES1 expression/activity could promote development of METH-PAH by increasing PMVEC apoptosis and small vessel loss.

Original languageEnglish (US)
Pages (from-to)L252-L266
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume313
Issue number2
DOIs
StatePublished - 2017

Fingerprint

Carboxylesterase
Methamphetamine
Pulmonary Hypertension
Wounds and Injuries
Lung
Endothelial Cells
Cytochrome P-450 CYP2D6
Autophagy
Apoptosis
Reactive Oxygen Species
Exome
Amphetamine
Microvessels
Endothelium
Fluorescent Antibody Technique
Mass Spectrometry
Nucleotides

ASJC Scopus subject areas

  • Physiology
  • Pulmonary and Respiratory Medicine
  • Cell Biology
  • Physiology (medical)

Cite this

Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension. / Orcholski, Mark E.; Khurshudyan, Artyom; Shamskhou, Elya A.; Yuan, Ke; Chen, Ian Y.; Kodani, Sean D.; Morisseau, Christophe; Hammock, Bruce D.; Hong, Ellen M.; Alexandrova, Ludmila; Alastalo, Tero Pekka; Berry, Gerald; Zamanian, Roham T.; De Jesus Perez, Vinicio A.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 313, No. 2, 2017, p. L252-L266.

Research output: Contribution to journalArticle

Orcholski, ME, Khurshudyan, A, Shamskhou, EA, Yuan, K, Chen, IY, Kodani, SD, Morisseau, C, Hammock, BD, Hong, EM, Alexandrova, L, Alastalo, TP, Berry, G, Zamanian, RT & De Jesus Perez, VA 2017, 'Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension', American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 313, no. 2, pp. L252-L266. https://doi.org/10.1152/ajplung.00453.2016
Orcholski, Mark E. ; Khurshudyan, Artyom ; Shamskhou, Elya A. ; Yuan, Ke ; Chen, Ian Y. ; Kodani, Sean D. ; Morisseau, Christophe ; Hammock, Bruce D. ; Hong, Ellen M. ; Alexandrova, Ludmila ; Alastalo, Tero Pekka ; Berry, Gerald ; Zamanian, Roham T. ; De Jesus Perez, Vinicio A. / Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2017 ; Vol. 313, No. 2. pp. L252-L266.
@article{2aeeac2e559b47e983fc46fc600e10d4,
title = "Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension is a complication of methamphetamine use (METH-PAH), but the pathogenic mechanisms are unknown. Given that cytochrome P450 2D6 (CYP2D6) and carboxylesterase 1 (CES1) are involved in metabolism of METH and other amphetamine-like compounds, we postulated that loss of function variants could contribute to METH-PAH. Although no difference in CYP2D6 expression was seen by lung immunofluorescence, CES1 expression was significantly reduced in endothelium of METH-PAH microvessels. Mass spectrometry analysis showed that healthy pulmonary microvascular endothelial cells (PMVECs) have the capacity to both internalize and metabolize METH. Furthermore, whole exome sequencing data from 18 METH-PAH patients revealed that 94.4{\%} of METH-PAH patients were heterozygous carriers of a single nucleotide variant (SNV; rs115629050) predicted to reduce CES1 activity. PMVECs transfected with this CES1 variant demonstrated significantly higher rates of METH-induced apoptosis. METH exposure results in increased formation of reactive oxygen species (ROS) and a compensatory autophagy response. Compared with healthy cells, CES1-deficient PMVECs lack a robust autophagy response despite higher ROS, which correlates with increased apoptosis. We propose that reduced CES1 expression/activity could promote development of METH-PAH by increasing PMVEC apoptosis and small vessel loss.",
author = "Orcholski, {Mark E.} and Artyom Khurshudyan and Shamskhou, {Elya A.} and Ke Yuan and Chen, {Ian Y.} and Kodani, {Sean D.} and Christophe Morisseau and Hammock, {Bruce D.} and Hong, {Ellen M.} and Ludmila Alexandrova and Alastalo, {Tero Pekka} and Gerald Berry and Zamanian, {Roham T.} and {De Jesus Perez}, {Vinicio A.}",
year = "2017",
doi = "10.1152/ajplung.00453.2016",
language = "English (US)",
volume = "313",
pages = "L252--L266",
journal = "American Journal of Physiology",
issn = "1040-0605",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension

AU - Orcholski, Mark E.

AU - Khurshudyan, Artyom

AU - Shamskhou, Elya A.

AU - Yuan, Ke

AU - Chen, Ian Y.

AU - Kodani, Sean D.

AU - Morisseau, Christophe

AU - Hammock, Bruce D.

AU - Hong, Ellen M.

AU - Alexandrova, Ludmila

AU - Alastalo, Tero Pekka

AU - Berry, Gerald

AU - Zamanian, Roham T.

AU - De Jesus Perez, Vinicio A.

PY - 2017

Y1 - 2017

N2 - Pulmonary arterial hypertension is a complication of methamphetamine use (METH-PAH), but the pathogenic mechanisms are unknown. Given that cytochrome P450 2D6 (CYP2D6) and carboxylesterase 1 (CES1) are involved in metabolism of METH and other amphetamine-like compounds, we postulated that loss of function variants could contribute to METH-PAH. Although no difference in CYP2D6 expression was seen by lung immunofluorescence, CES1 expression was significantly reduced in endothelium of METH-PAH microvessels. Mass spectrometry analysis showed that healthy pulmonary microvascular endothelial cells (PMVECs) have the capacity to both internalize and metabolize METH. Furthermore, whole exome sequencing data from 18 METH-PAH patients revealed that 94.4% of METH-PAH patients were heterozygous carriers of a single nucleotide variant (SNV; rs115629050) predicted to reduce CES1 activity. PMVECs transfected with this CES1 variant demonstrated significantly higher rates of METH-induced apoptosis. METH exposure results in increased formation of reactive oxygen species (ROS) and a compensatory autophagy response. Compared with healthy cells, CES1-deficient PMVECs lack a robust autophagy response despite higher ROS, which correlates with increased apoptosis. We propose that reduced CES1 expression/activity could promote development of METH-PAH by increasing PMVEC apoptosis and small vessel loss.

AB - Pulmonary arterial hypertension is a complication of methamphetamine use (METH-PAH), but the pathogenic mechanisms are unknown. Given that cytochrome P450 2D6 (CYP2D6) and carboxylesterase 1 (CES1) are involved in metabolism of METH and other amphetamine-like compounds, we postulated that loss of function variants could contribute to METH-PAH. Although no difference in CYP2D6 expression was seen by lung immunofluorescence, CES1 expression was significantly reduced in endothelium of METH-PAH microvessels. Mass spectrometry analysis showed that healthy pulmonary microvascular endothelial cells (PMVECs) have the capacity to both internalize and metabolize METH. Furthermore, whole exome sequencing data from 18 METH-PAH patients revealed that 94.4% of METH-PAH patients were heterozygous carriers of a single nucleotide variant (SNV; rs115629050) predicted to reduce CES1 activity. PMVECs transfected with this CES1 variant demonstrated significantly higher rates of METH-induced apoptosis. METH exposure results in increased formation of reactive oxygen species (ROS) and a compensatory autophagy response. Compared with healthy cells, CES1-deficient PMVECs lack a robust autophagy response despite higher ROS, which correlates with increased apoptosis. We propose that reduced CES1 expression/activity could promote development of METH-PAH by increasing PMVEC apoptosis and small vessel loss.

UR - http://www.scopus.com/inward/record.url?scp=85026740060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026740060&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00453.2016

DO - 10.1152/ajplung.00453.2016

M3 - Article

C2 - 28473326

AN - SCOPUS:85026740060

VL - 313

SP - L252-L266

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 1040-0605

IS - 2

ER -